"DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer."
Send me $40K and I'll say ALMOST anything.
Diwan's name does not appear. Nor is their any mention of his relationship with the licensee.
And the Zach's Phd puts forth the same shaky proposition that NNVC's friend at Benzinga offered up:
"This is an important inflection point for NanoViricides as it is now transitioning to clinical-stage operations following a long development timeline as a pre-clinical company."
It is? NNVC is licensing 2 drugs to "someone else" to conduct the trials....the licensee will be conducting clinical-stage operations, not NNVC.
Some might say that that's just semantics. I prefer to call it misleading. And it's no small thing. Investors have been waiting for NNVC to run clinical trial for a long, long time....why aren't they actually doing it themselves, instead of just intimating that they are?
I didn't miss this.....
"Karveer has begun clinical development and evaluation of those two drugs and has obtained regulatory permissions to conduct clinical evaluation of them in India"
.....but it doesn't answer the question.
We've been we'll seeing for well over a decade.
No matter what it is or who commenced it, I'm against it!
....Groucho
AI
Market Data 
Markets 
